Antibody Variant Libraries for High-Affinity CDR Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The design of therapeutic antibodies is challenging due to the need to balance immunological effects with efficacy, necessitating the development of compositions and methods for optimizing antibody properties.
Innovation Solution
Nucleic acid libraries comprising a plurality of sequences encoding for antibodies or antibody fragments with predetermined mutations are generated, allowing for the selection of variants with enhanced binding affinity, including computerized systems for synthesizing and optimizing these libraries to enrich sequences with higher binding capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional antibody design methods are used, then the design process is simpler, but the binding affinity and efficacy optimization is insufficient
Solution Approach 1:
The patent applies preliminary action by pre-designing nucleic acid libraries with predetermined mutations in CDR regions before screening. The libraries are constructed with specific mutation patterns (e.g., 1-3 mutations per CDR) based on computational analysis and known immunological constraints, allowing systematic exploration of affinity-enhancing variants without random screening of all possible mutations.
Solution Approach 2:
The patent applies local quality by focusing mutations specifically in the CDR (complementarity-determining region) of the antibody sequences, which are the local regions responsible for antigen binding. The framework regions are kept relatively unchanged while introducing controlled diversity in the CDR loops, thereby optimizing binding affinity without compromising overall antibody structure and immunological properties.
2Reliability
If large numbers of variant sequences are included in the library, then the probability of finding high-affinity antibodies increases, but the complexity of library management and analysis increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody sequence into distinct functional regions (framework regions and CDR regions) and treating them differently in library construction. The framework regions are kept constant or minimally varied, while the CDR regions are the focus of mutation introduction. This segmentation allows manageable library sizes while still exploring sufficient sequence space to find high-affinity variants.
Solution Approach 2:
The patent applies parameter changes by systematically varying specific parameters such as the number of mutations per CDR (1-3 mutations), the types of amino acid substitutions (conservative to non-conservative), and the combination patterns across different CDRs. These controlled parameter changes generate diverse yet manageable library configurations that balance exploratory power with analytical tractability.
3Manufacturing precision
If multiple mutations are introduced in each CDR, then the binding affinity can be significantly improved, but the risk of compromising antibody stability and immunological properties increases
Solution Approach 1:
The patent applies preliminary anti-action by pre-filtering and pre-selecting mutation combinations that are computationally predicted to maintain structural stability and immunological properties. Before library construction, computational models assess the potential impact of mutations on antibody folding, stability, and antigen recognition, excluding combinations that are likely to compromise these properties. This preliminary filtering prevents the introduction of destabilizing mutations while still allowing affinity-enhancing changes.
Data Source
AI summary
Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.